Background Despite guidelines establishing the need to perform comprehensive paediatric drug development programs, pivotal trials in children with epilepsy have been completed mostly in Phase IV as a postapproval replication of adult data. However, it has been shown that the treatment response in children can differ from that in adults. It has not been investigated whether differences in drug effect between adults and children might occur in the treatment of drug-resistant partial epilepsy, although such differences may have a substantial impact on the design and results of paediatric randomised controlled trials (RCTs). Methods and Findings Three electronic databases were searched for RCTs investigating any antiepileptic drug (AED) in the add-on treatment of drug-resistant partial epilepsy in both children and adults. The treatment effect was compared between the two age groups using the ratio of the relative risk (RR) of the 50% responder rate between active AEDs treatment and placebo groups, as well as meta-regression. Differences in the response to placebo and to active treatment were searched using logistic regression. A comparable approach was used for analysing secondary endpoints, including seizure-free rate, total and adverse events-related withdrawal rates, and withdrawal rate for seizure aggravation. Five AEDs were evaluated in both adults and children with drug-resistant partial epilepsy in 32 RCTs. The treatment effect was significantly lower in children than in adults (RR ratio: 0.67 [95% confidence interval (CI) 0.51–0.89]; p = 0.02 by meta-regression). This difference was related to an age-dependent variation in the response to placebo, with a higher rate in children than in adults (19% versus 9.9%, p < 0.001), whereas no significant difference was observed in the response to active treatment (37.2% versus 30.4%, p = 0.364). The relative risk of the total withdrawal rate was also significantly lower in children than in adults (RR ratio: 0.65 [95% CI 0.43–0.98], p = 0.004 by metaregression), due to higher withdrawal rate for seizure aggravation in children (5.6%) than in adults (0.7%) receiving placebo (p < 0.001). Finally, there was no significant difference in the seizure-free rate between adult and paediatric studies. Conclusions Children with drug-resistant partial epilepsy receiving placebo in double-blind RCTs demonstrated significantly greater 50% responder rate than adults, probably reflecting increased placebo and regression to the mean effects. Paediatric clinical trial designs should account for these age-dependent variations
References
[1]
Guerrini R (2006) Epilepsy in children. Lancet 367: 499–524.
[2]
Garofalo E (2006) Obtaining pediatric indications for new anti-epileptic drugs: how and when. Epilepsy Res 68: 38–42.
[3]
Schmidt B (2007) Clinical development of antiepileptic drugs in adults. Neurotherapeutics 4: 62–69.
Pellock JM (1998) Pediatric trials: practical issues. Special populations and trial design. Adv Neurol 76: 167–171.
[6]
Steinbrook R (2002) Testing medications in children. N Engl J Med 347: 1462–1470.
[7]
Perucca E (2006) Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age. Clin Pharmacokinet 45: 351–363.
[8]
Shinnar S, Pellock JM (2005) The trials and tribulations of pediatric drug trials. Neurology 65: 1348–1349.
[9]
Sandler A (2005) Placebo effects in developmental disabilities: implications for research and practice. Ment Retard Dev Disabil Res Rev 11: 164–170.
[10]
Fernandes R, Ferreira JJ, Sampaio C (2008) The placebo response in studies of acute migraine. J Pediatr 152: 527–33. 533.e.l.
[11]
Lewis DW, Winner P, Wasiewski W (2005) The placebo responder rate in children and adolescents. Headache 45: 232–239.
[12]
Rothner AD, Wasiewski W, Winner P, Lewis D, Stankowski J (2006) Zolmitriptan oral tablet in migraine treatment: high placebo responses in adolescents. Headache 46: 101–109.
[13]
[No authors listed] (1993) Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). The Felbamate Study Group in Lennox-Gastaut Syndrome. N Engl J Med 328: 29–33.
[14]
Beran RG, Berkovic SF, Dunagan FM, Vajda FJ, Danta G, et al. (1998) Double-blind, placebo-controlled, crossover study of lamotrigine in treatment-resistant generalised epilepsy. Epilepsia 39: 1329–1333.
[15]
Berkovic SF, Knowlton RC, Leroy RF, Schiemann J, Falter U (2007) Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy. Neurology 69: 1751–1760.
[16]
Biton V, Montouris GD, Ritter F, Riviello JJ, Reife R, et al. (1999) A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC Study Group. Neurology 52: 1330–1337.
[17]
Biton V, Sackellares JC, Vuong A, Hammer AE, Barrett PS, et al. (2005) Double-blind, placebo-controlled study of lamotrigine in primary generalized tonic-clonic seizures. Neurology 65: 1737–1743.
[18]
Chadwick D, Leiderman DB, Sauermann W, Alexander J, Garofalo E (1996) Gabapentin in generalized seizures. Epilepsy Res 25: 191–197.
[19]
Glauser T, Kluger G, Sachdeo R, Krauss G, Perdomo C, et al. (2008) Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology 17: 1950–1958.
[20]
Motte J, Trevathan E, Arvidsson JF, Barrera MN, Mullens EL, et al. (1997) Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group. N Engl J Med 337: 1807–1812.
[21]
Sachdeo RC, Glauser TA, Ritter F, Reife R, Lim P, et al. (1999) A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group. Neurology 52: 1882–1887.
[22]
[No authors listed] (1989) Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia 30: 389–399.
[23]
French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, et al. (2004) Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 62: 1261–1273.
[24]
Gumnit RJ, Walczak TS (2001) Guidelines for essential services, personnel, and facilities in specialized epilepsy centers in the United States. Epilepsia 42: 804–814.
[25]
Perruca E (1998) Pharmacoresistance in epilepsy: how should it be defined. CNS Drugs 10: 171–179.
[26]
Regesta G, Tanganelli P (1999) Clinical aspects and biological bases of drug-resistant epilepsies. Epilepsy Res 34: 109–122.
[27]
European Medicines Agency (2001) International Conference on Harmonisation. ICH topic E11 clinical investigation of medicinal products in the paediatric population. Available: http://www.emea.eu/pdfs/human/ich/271199？EN.pdf. Accessed 07 July 2008.
[28]
Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, et al. (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary. Control Clin Trials 17: 1–12.
[29]
Gazzola DM, Balcer LJ, French JA (2007) Seizure-free outcome in randomized add-on trials of the new antiepileptic drugs. Epilepsia 48: 1303–1307.
[30]
Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539–1558.
[31]
Cucherat M (2000) EasyMA Sofware Version 2000. Available: http://www.spc.univ-lyon1.fr/easyma.net/. Accessed 07 July 08.
[32]
Cucherat M, Boissel JP, Leizorovicz A, Haugh MC (1997) EasyMA: a program for the meta-analysis of clinical trials. Comput Methods Programs Biomed 53: 187–190.
[33]
Rosenfeld W, Abou-Khalil B, Reife R, Hegadus R, Pledger G, et al. (1996) Placebo-controlled trial of topiramate as adjunctive therapy to carbamazepine or phenitoine for partial onset seizures. Epilepsia 37: 153.
[34]
Schmidt D, Ried RS, Rapp P (1993) Add-on treatment with Lamotrigine for intractable partial epilepsy: a placebo-controlled, cross-over trial. Epilepsia 34: 66.
Ramaratnam S, Marson AG, Baker GA (2001) Lamotrigine add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev CD001909. Available: http://www.cochrane.org/reviews/en/ab001？909.html. Accessed 07 July 08.
[37]
Duchowny M, Pellock JM, Graf WD, Billard C, Gilman J, et al. (1999) A placebo-controlled trial of lamotrigine add-on therapy for partial seizures in children. Lamictal Pediatric Partial Seizure Study Group. Neurology 53: 1724–1731.
Marson AG, Hutton JL, Leach JP, Castillo S, Schmidt D, et al. (2001) Levetiracetam, oxcarbazepine, remacemide and zonisamide for drug resistant localization-related epilepsy: a systematic review. Epilepsy Res 46: 259–270.
[50]
Marson AG, Kadir ZA, Hutton JL, Chadwick DW (1997) The new antiepileptic drugs: a systematic review of their efficacy and tolerability. Epilepsia 38: 859–880.
[51]
Otoul C, Arrigo C, van Rijckevorsel K, French JA (2005) Meta-analysis and indirect comparisons of levetiracetam with other second-generation antiepileptic drugs in partial epilepsy. Clin Neuropharmacol 28: 72–78.
[52]
[No authors listed] (2006) Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medical products for paediatric use. Official Journal of the European Union. Available: http://ec.europa.eu/enterprise/pharmaceu？ticals/eudralex/vol-1/reg_2006_1901/reg_？2006_1901_en.pdf. Accessed 07 July 08.
[53]
National Institutes of Health (1998) NIH policy and guidelines on the inclusion of children as participants in research involving human subjects. Available: http://grants.nih.gov/grants/guide/notic？e-files/not98–024.html. Accessed 07 July 08.
[54]
Appleton R, Fichtner K, LaMoreaux L, Alexander J, Halsall G, et al. (1999) Gabapentin as add-on therapy in children with refractory partial seizures: a 12-week, multicentre, double-blind, placebo-controlled study. Gabapentin Paediatric Study Group. Epilepsia 40: 1147–1154.
[55]
Elterman RD, Glauser TA, Wyllie E, Reife R, Wu SC, et al. (1999) A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children. Topiramate YP Study Group. Neurology 52: 1338–1344.
[56]
Anhut H, Ashman P, Feuerstein TJ, Sauermann W, Saunders M, et al. (1994) Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study. The International Gabapentin Study Group. Epilepsia 35: 795–801.
[57]
Tassinari CA, Michelucci R, Chauvel P, Chodkiewicz J, Shorvon S, et al. (1996) Double-blind, placebo-controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy. Epilepsia 37: 763–768.
[58]
Yamauchi T, Kaneko S, Yagi K, Sase S (2006) Treatment of partial seizures with gabapentin: double-blind, placebo-controlled, parallel-group study. Psychiatry Clin Neurosci 60: 507–515.
[59]
Pina-Garza JE, Espinoza R, Nordli D, Bennett DA, Spirito S, et al. (2005) Oxcarbazepine adjunctive therapy in infants and young children with partial seizures. Neurology 65: 1370–1375.
[60]
Chiron C, Tonnelier S, Rey E, Brunet ML, Tran A, et al. (2006) Stiripentol in childhood partial epilepsy: randomized placebo-controlled trial with enrichment and withdrawal design. J Child Neurol 21: 496–502.
[61]
Chiron C, Dulac O, Gram L (1996) Vigabatrin withdrawal randomized study in children. Epilepsy Res 25: 209–215.
[62]
Chiron C, Dulac O, Pons G (2008) Antiepileptic drug development in children: considerations for a revisited strategy. Drugs 68: 17–25.
[63]
Pina-Garza JE, Levisohn P, Gucuyener K, Mikati MA, Warnock CR, et al. (2007) Adjunctive lamotrigine for partial seizures in patients aged 1 to 24 months. Neurology.
[64]
[No authors listed] (1990) Gabapentin in partial epilepsy. UK Gabapentin Study Group. Lancet 335: 1114–1117.
[65]
Sivenius J, Kalviainen R, Ylinen A, Riekkinen P (1991) Double-blind study of Gabapentin in the treatment of partial seizures. Epilepsia 32: 539–542.
[66]
[No authors listed] (1993) Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled, parallel-group study. The US Gabapentin Study Group No. 5. Neurology 43: 2292–2298.
[67]
Binnie CD, Debets RM, Engelsman M, Meijer JW, Meinardi H, et al. (1989) Double-blind crossover trial of lamotrigine (Lamictal) as add-on therapy in intractable epilepsy. Epilepsy Res 4: 222–229.
[68]
Jawad S, Richens A, Goodwin G, Yuen WC (1989) Controlled trial of lamotrigine (Lamictal) for refractory partial seizures. Epilepsia 30: 356–363.
[69]
Loiseau P, Yuen AW, Duche B, Menager T, Arne-Bes MC (1990) A randomised double-blind placebo-controlled crossover add-on trial of lamotrigine in patients with treatment-resistant partial seizures. Epilepsy Res 7: 136–145.
[70]
Matsuo F, Bergen D, Faught E, Messenheimer JA, Dren AT, et al. (1993) Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. U.S. Lamotrigine Protocol 0.5 Clinical Trial Group. Neurology 43: 2284–2291.
[71]
Schapel GJ, Beran RG, Vajda FJ, Berkovic SF, Mashford ML, et al. (1993) Double-blind, placebo controlled, crossover study of lamotrigine in treatment resistant partial seizures. J Neurol Neurosurg Psychiatry 56: 448–453.
[72]
Smith D, Baker G, Davies G, Dewey M, Chadwick DW (1993) Outcomes of add-on treatment with lamotrigine in partial epilepsy. Epilepsia 34: 312–322.
[73]
Messenheimer J, Ramsay RE, Willmore LJ, Leroy RF, Zielinski JJ, et al. (1994) Lamotrigine therapy for partial seizures: a multicenter, placebo-controlled, double-blind, cross-over trial. Epilepsia 35: 113–121.
[74]
Boas J, Dam M, Friis ML, Kristensen O, Pedersen B, et al. (1996) Controlled trial of lamotrigine (Lamictal) for treatment-resistant partial seizures. Acta Neurol Scand 94: 247–252.
[75]
Ben-Menachem E, Falter U (2000) Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group. Epilepsia 41: 1276–1283.
[76]
Cereghino JJ, Biton V, Abou-Khalil B, Dreifuss F, Gauer LJ, et al. (2000) Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 55: 236–242.
[77]
Shorvon SD, Lowenthal A, Janz D, Bielen E, Loiseau P (2000) Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group. Epilepsia 41: 1179–1186.
[78]
Tsai JJ, Yen DJ, Hsih MS, Chen SS, Hiersemenzel R, et al. (2006) Efficacy and safety of levetiracetam (up to 2000 mg/day) in Taiwanese patients with refractory partial seizures: a multicenter, randomized, double-blind, placebo-controlled study. Epilepsia 47: 72–81.
[79]
Glauser TA, Ayala R, Elterman RD, Mitchell WG, Van Orman CB, et al. (2006) Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. Neurology 66: 1654–1660.
[80]
Barcs G, Walker EB, Elger CE, Scaramelli A, Stefan H, et al. (2000) Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy. Epilepsia 41: 1597–1607.
[81]
Glauser TA, Nigro M, Sachdeo R, Pasteris LA, Weinstein S, et al. (2000) Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group. Neurology 54: 2237–2244.
[82]
Ben-Menachem E, Henriksen O, Dam M, Mikkelsen M, Schmidt D, et al. (1996) Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia 37: 539–543.
[83]
Faught E, Wilder BJ, Ramsay RE, Reife RA, Kramer LD, et al. (1996) Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Topiramate YD Study Group. Neurology 46: 1684–1690.
[84]
Privitera M, Fincham R, Penry J, Reife R, Kramer L, et al. (1996) Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages. Topiramate YE Study Group. Neurology 46: 1678–1683.
[85]
Sharief M, Viteri C, Ben-Menachem E, Weber M, Reife R, et al. (1996) Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy. Epilepsy Res 25: 217–224.
[86]
Korean (1999) Topiramate in medically intractable partial epilepsies: double-blind placebo-controlled randomized parallel group trial. Korean Topiramate Study Group. Epilepsia 40: 1767–1774.
[87]
Yen DJ, Yu HY, Guo YC, Chen C, Yiu CH, et al. (2000) A double-blind, placebo-controlled study of topiramate in adult patients with refractory partial epilepsy. Epilepsia 41: 1162–1166.
